News
Please, enter cell line, author or any other phrase or word you would like to search for.
PHI receives 18 MSEK through share options
On June 13, 2019, the exercise period of the TO 2 share options in Phase Holographic Imaging (“PHI”) ended. 632 520 (97.6 %) of the 648 338 outstanding options were exercised. PHI will thus receive approx. 17.8 MSEK before issuing expenses, which are expected to amount to approx. 0.8 MSEK.
PHI and leading supplier of cell analysis instrumentation sign agreement
Phase Holographic Imaging (PHI) and a major publicly traded international supplier of laboratory equipment and cell analysis instrumentation have entered an agreement aiming to determine the scope and nature of a future partnership. The agreement is a result of discussions between the company management teams, over an extended period time.
Investerarträff 28 maj 2019
Phase Holographic Imaging, inbjuder till investerarträff för befintliga aktieägare och övriga intresserade tisdagen den 28 maj 2019 klockan 16:30 i bolagets lokaler, Scheelevägen 22 i Lund.
PHI establish US subsidiary to foster US partnerships
As part of the ongoing expansion of activities on the US market, the Board of Directors of Phase Holographic Imaging (PHI) has initiated the process of establishing a fully owned subsidiary in the US.
PHI releases App Suite 2 – more apps and greater applicability
App Suite 2 is the second release in a series of planned App Suite releases, developed to provide automated live-cell studies to researchers worldwide in an unprecedented user-friendly workflow, using PHI’s HoloMonitor-technology.
Chairman Klas Cramborn has passed away after a period of illness
PHI expands European distributor network
System-c bioprocess, Aurogene and Labsoft have recently been appointed to respectively represent Phase Holographic Imaging (PHI) in France, Italy and Poland.
Interim Report for the third quarter
For the first time, sales during the past 12 months reached 5 MSEK. Since our previous report, much effort has gone into implementing the ambitious market expansion made possible by the capital acquisition this summer.
Leading life science tools company enters technology assessment agreement with PHI
A major publicly traded life science tools company has entered a technology assessment agreement with Phase Holographic Imaging (PHI). The purpose of the agreement is to assess PHI’s Holo¬Monitor technology for cell biology applications, primarily within immuno-oncology.
PHI and BioSpherix expand marketing partnership after scientific evaluation
In June 2018, Phase Holographic Imaging (PHI) and BioSpherix Medical entered a collaboration agreement, aiming to co-market the companies’ complementary product lines. BioSpherix develops and market advanced hermetically sealed cell incubators for the control and optimization of cell culture environments.